Table 4. Comparison of clinicopathological features of PD-L1-positive extranodal LBCL and PD-L1-negative extranodal LBCL.
| PD-L1-positive extranodal LBCL (n=18) |
PD-L1-negative extranodal LBCL (n=16) |
P-value | |
|---|---|---|---|
| Age [years; median (range)] | 72 (43-86) | 72 (51-83) | 0.931 |
| Sex, male [n (%)] | 8 (44) | 9 (56) | 0.492 |
| Disturbance of consciousness [n (%)] | 4 (22) | 5 (31) | 0.703 |
| Hepatomegaly [n (%)] | 3/16 (19) | 3/15 (20) | 1.000 |
| Splenomegaly [n (%)] | 4/16 (25) | 5/15 (33) | 0.704 |
| Hemophagocytosis [n (%)] | 6/12 (50) | 6/11 (55) | 1.000 |
| Peripheral blood involvement [n (%)] | 0 (0.0) | 3 (19) | 0.094 |
| Ann Arbor stage III/IV [n (%)] | 12 (67) | 11 (69) | 1.000 |
| WBC [×102/μl; median (range)] | 63 (23-128) | 59 (21-132) | 0.671 |
| Hb [g/dl; median (range)] | 11 (6.3-14.3) | 10 (7-15.6) | 0.601 |
| PLT [×104/μl; median (range)] | 19 (2-50) | 18 (1.2-58) | 0.836 |
| LD [U/l; median (range)] | 529 (142-2,018) | 720 (172-1,862) | 0.270 |
| Ferritin [ng/ml; median (range)] | 2,415 (11.2-22,923) | 2,616 (21.2-29,070) | 0.946 |
| sIL-2R [U/ml; median (range)] | 5,284 (225-37,583) | 6,193 (340-38,000) | 0.796 |
| CD5-positive [n (%)] | 4 (22) | 7 (44) | 0.274 |
| CD10-positive [n (%)] | 5 (28) | 4 (25) | 1.000 |
| Bcl-2-positive [n (%)] | 17 (94) | 15 (94) | 1.000 |
| Bcl-6-positive [n (%)] | 15 (83) | 8 (50) | 0.066 |
| IRF4/MUM-1-positive [n (%)] | 18 (100) | 11 (69) | 0.016* |
| CD29-positive [n (%)] | 7 (39) | 2 (13) | 0.125 |
| CD54-positive [n (%)] | 11 (61) | 6 (38) | 0.169 |
| Ki-67 labeling index [%; median (range)] | 65 (30-96) | 68 (5-100) | 0.695 |
Abbreviations: LBCL, large B-cell lymphoma; Hb, hemoglobin; LD, lactate dehydrogenase; M, male; PD-L1, programmed death-ligand 1; PLT, platelet; sIL2R, soluble interleukin 2 receptor; WBC, white blood cell.
*P-value < 0.05